Pelvital, a leading innovator in women's health, is pleased to announce the successful closing of a $2.68 million seed funding round for Flyte, a revolutionary, accessible, and clinically proven treatment for stress urinary incontinence (SUI) and weakened pelvic floor muscles. This funding milestone emphasizes Flyte's significant impact in addressing an underserved health concern among women. Flyte is the only at-home intravaginal device that delivers the proven treatment modality of mechanotherapy to treat SUI and strengthen pelvic floor muscles quickly and effectively.

The investment round was led by Boomerang Ventures, a venture capital firm focused on transformative connected health. Other participants in the round include VisionTech Partners, Wisconsin Investment Partners, and Edward Bergmark, PhD, Founder and former CEO of Optum.

Pelvital is a women's health medical device company empowering women and clinicians to restore pelvic health with effective, convenient products backed by strong clinical evidence. Their first product, Flyte®, is an FDA-cleared novel in-home treatment for stress urinary incontinence and weakened pelvic floor muscles. Unlike electrical stimulation devices or Kegel trainers, Flyte delivers mechanotherapy, a foundational treatment modality that when paired with an active pelvic floor contraction stimulates tissue regeneration and the creation of neuromuscular memory. Flyte also supports women with a complimentary Ask A (Pelvic) Physical Therapist Service staffed by Doctors of Physical Therapy specializing in pelvic floor health.